SIP
VTAE

Stoneridge Investment Partners’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Stoneridge Investment Partners’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-22,157
Closed -$169K – 301
2014
Q3 		$169K Buy
+22,157
New +$172K 0.03% 232

Other funds holding VTAE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stoneridge Investment Partners's VTAE Position: Q4 2014 in Review

Stoneridge Investment Partners sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2014, closing a stake of 22,157 shares — an estimated $169K sold.

Stoneridge Investment Partners first reported a position in VTAE in Q3 2014 and held it in 1 quarter. The position peaked at $169K in Q3 2014. 34 funds tracked by Wall St. Rank hold VTAE as of Q4 2014.

  • Stoneridge Investment Partners reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2014 after selling out during the quarter.
  • Stoneridge Investment Partners sold 22,157 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2014, an estimated $169K.
  • Stoneridge Investment Partners first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2014 and held it in 1 quarter.
  • Stoneridge Investment Partners's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $169K in Q3 2014.
  • 34 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2014.

Based on Stoneridge Investment Partners's 13F filing for Q4 2014, filed 26 Jan 2015.